RECURRENT T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo shows promise for Hard-to-Treat lymphomas
Disease control OngoingThis early-stage trial is testing a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study aims to find the safest dose and see if the combination can shrink or stabilize the cancer…
Matched conditions: RECURRENT T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Cancer-killing virus plus immune booster shows promise for rare skin tumors
Disease control OngoingThis study tests a two-step treatment for people with rare skin cancers or certain lymphomas that haven't responded to standard care. First, patients receive a virus-based therapy (talimogene laherparepvec) that infects and kills tumor cells. Then, they also get an immunotherapy …
Matched conditions: RECURRENT T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC